חוב לטווח קצר להון: Mineralys Therapeutics (MLYS)

Mineralys Therapeutics (MLYS) price action demonstrates a dependence on the results of final trials for its primary drug and FDA regulatory approval. The business is currently focused on completing the final testing phase of its innovative molecule to facilitate market expansion. The current metric stands at 0.01, confirming its status as a promising brand that has earned physician trust through new therapies for critical pressure.

The potential of Mineralys Therapeutics (MLYS) in the hypertension therapy segment requires stable funding, making the short-term debt to equity ratio chart critical for assessing current solvency. This metric compares obligations maturing within one year against shareholders' equity, allowing investors to determine the company's reliance on short-term borrowing and the risk of liquidity loss during a shift in the market cycle.